Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2.

Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2.
复制标题

SARS冠状病毒2感染后刺突蛋白抗体的长期持续性和抗体动力学的预测模型。

DOI:
10.1093/cid/ciab607
复制
发表时间:
2022-04-09
期刊:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子:
--
通讯作者:
COVID-19 Staff Testing of Antibody Responses Study (Co-Stars) team
COVID-19 Staff Testing of Antibody Responses Study (Co-Stars) team
中科院分区:
其他
文献类型:
--
作者:
Grandjean L;Saso A;Torres Ortiz A;Lam T;Hatcher J;Thistlethwayte R;Harris M;Best T;Johnson M;Wagstaffe H;Ralph E;Mai A;Colijn C;Breuer J;Buckland M;Gilmour K;Goldblatt D;COVID-19 Staff Testing of Antibody Responses Study (Co-Stars) team

文献摘要

参考文献

被引文献

相似文献

严重急性呼吸道综合征冠状病毒2型(SARS-CoV-2)的抗体已被证明可以在体外中和病毒,并在再次暴露的动物攻击模型中预防疾病。然而,目前对SARS-CoV-2体液动力学和寿命的理解是相互矛盾的。COVID-19工作人员抗体反应测试研究(Co-Stars)前瞻性招募了3679名医护人员,以平行全面表征SARS-CoV-2刺突蛋白(S)、受体结合结构域和核蛋白(N)抗体的动力学。筛选血清学阳性的参与者使用Meso Scale Discovery Assay每月进行一次连续血清学检测,最长持续7个月。生存分析确定了血清逆转的比例,而2个分层伽马模型预测了长期抗体轨迹的上限和下限。从349名血清阳性参与者中共提供了1163份每月样本。在出现症状后200天,>95%的参与者可检测到S抗体,而75%的参与者可检测到N抗体。使用“连续衰减”模型预测在95%的参与者中可检测到S抗体,直到465天(95%置信区间,370-575天),并无限期地使用“衰减到平台”模型来解释长寿浆细胞的抗体分泌。S-抗体滴度与体外替代中和强烈相关(R2 = 0.72)。然而,N抗体迅速衰减,半衰期为60天(95%置信区间,52-68天)。本文提供的Co-Stars数据为中和S抗体的长期持续性提供了证据。这对SARS-CoV-2感染后功能性免疫的持续时间具有重要意义。相反,在未来的血清阳性率研究和公共卫生决策中必须考虑N抗体的快速衰减。这是第一项建立能够预测SARS-CoV-2感染后长期体液动力学的数学框架的研究。NCT 04380896。我们证明了在严重急性呼吸综合征冠状病毒2型感染后长达200天的349名患者的系列样本中刺突蛋白的持续存在和核蛋白抗体的衰减,并提供了一个数学建模框架来预测长期免疫应答。
Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been shown to neutralize the virus in vitro and prevent disease in animal challenge models on reexposure. However, the current understanding of SARS-CoV-2 humoral dynamics and longevity is conflicting. The COVID-19 Staff Testing of Antibody Responses Study (Co-Stars) prospectively enrolled 3679 healthcare workers to comprehensively characterize the kinetics of SARS-CoV-2 spike protein (S), receptor-binding domain, and nucleoprotein (N) antibodies in parallel. Participants screening seropositive had serial monthly serological testing for a maximum of 7 months with the Meso Scale Discovery Assay. Survival analysis determined the proportion of seroreversion, while 2 hierarchical gamma models predicted the upper and lower bounds of long-term antibody trajectory. A total of 1163 monthly samples were provided from 349 seropositive participants. At 200 days after symptoms, >95% of participants had detectable S antibodies, compared with 75% with detectable N antibodies. S antibody was predicted to remain detectable in 95% of participants until 465 days (95% confidence interval, 370–575 days) using a “continuous-decay” model and indefinitely using a “decay-to-plateau” model to account for antibody secretion by long-lived plasma cells. S-antibody titers were correlated strongly with surrogate neutralization in vitro (R2 = 0.72). N antibodies, however, decayed rapidly with a half-life of 60 days (95% confidence interval, 52–68 days). The Co-Stars data presented here provide evidence for long-term persistence of neutralizing S antibodies. This has important implications for the duration of functional immunity after SARS-CoV-2 infection. In contrast, the rapid decay of N antibodies must be considered in future seroprevalence studies and public health decision-making. This is the first study to establish a mathematical framework capable of predicting long-term humoral dynamics after SARS-CoV-2 infection. NCT04380896. We demonstrate persistence of spike protein and decay of nucleoprotein antibody in serial samples from 349 patients up to 200 days after severe acute respiratory syndrome coronavirus 2 infection and provide a mathematical modeling framework to predict long-term immune responses.
DOI: 10.1111/j.1440-1843.2006.00783.x
发表时间: 2006-01-01
期刊: RESPIROLOGY
影响因子: 6.9
作者:
Mo, HY;Zeng, GQ;Zhong, NS
通讯作者: Zhong, NS
DOI: 10.1126/science.abb5793
发表时间: 2020-05-22
期刊: SCIENCE
影响因子: 56.9
作者:
Kissler, Stephen M.;Tedijanto, Christine;Lipsitch, Marc
通讯作者: Lipsitch, Marc
DOI: 10.1016/j.immuni.2020.04.023
发表时间: 2020-06-16
期刊: IMMUNITY
影响因子: 32.4
作者:
Ni, Ling;Ye, Fang;Dong, Chen
通讯作者: Dong, Chen
DOI: 10.1126/sciimmunol.abe5511
发表时间: 2020-10-08
期刊: Science immunology
影响因子: 24.8
作者:
Isho B;Abe KT;Zuo M;Jamal AJ;Rathod B;Wang JH;Li Z;Chao G;Rojas OL;Bang YM;Pu A;Christie-Holmes N;Gervais C;Ceccarelli D;Samavarchi-Tehrani P;Guvenc F;Budylowski P;Li A;Paterson A;Yue FY;Marin LM;Caldwell L;Wrana JL;Colwill K;Sicheri F;Mubareka S;Gray-Owen SD;Drews SJ;Siqueira WL;Barrios-Rodiles M;Ostrowski M;Rini JM;Durocher Y;McGeer AJ;Gommerman JL;Gingras AC
通讯作者: Gingras AC
DOI: 10.1007/s10875-021-00997-6
发表时间: 2021-07
影响因子: 9.1
作者:
Hicks J;Klumpp-Thomas C;Kalish H;Shunmugavel A;Mehalko J;Denson JP;Snead KR;Drew M;Corbett KS;Graham BS;Hall MD;Memoli MJ;Esposito D;Sadtler K
通讯作者: Sadtler K